Mesoblast highlights Ryoncil profits supporting pipeline growth
Mesoblast reports that commercial revenues from its cell therapy Ryoncil are funding expansion of its clinical development pipeline. The company says sales reduce reliance on external financing and support trials targeting inflammatory, cardiovascular, and chronic pain indications.
Why it mattersRyoncil sales are funding Mesoblast's clinical pipeline and manufacturing expansion.
Entities Mentioned
MesoblastTectonic TherapeuticLongeveronLinnaeusVivtexNovo Nordisk
People Mentioned
François Nader